Tisagenlecleucel

Latest news

Tag

Tisagenlecleucel for Post-Transplant Relapse in Young Acute Lymphoblastic Leukemia Patients: European Real-World Determinants of Outcome

This study evaluates the outcomes and critical factors influencing the success of tisagenlecleucel therapy for children and young adults with B-cell acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplant across Euro

Sep 16, 2026

Hematology-Oncology

TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL

A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Pa

Apr 12, 2026

Clinical Updates

Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial

Tisagenlecleucel CAR T-cell therapy demonstrates durable responses and manageable safety in adults with relapsed or refractory diffuse large B-cell lymphoma, with 5-year data supporting its curative potential in select patients.

Dec 8, 2025Sign in to read